PMID- 19282308
OWN - NLM
STAT- MEDLINE
DCOM- 20100219
LR  - 20151119
IS  - 1468-2060 (Electronic)
IS  - 0003-4967 (Linking)
VI  - 69
IP  - 2
DP  - 2010 Feb
TI  - Women with rheumatoid arthritis negative for anti-cyclic citrullinated peptide 
      and rheumatoid factor are more likely to improve during pregnancy, whereas in 
      autoantibody-positive women autoantibody levels are not influenced by pregnancy.
PG  - 420-3
LID - 10.1136/ard.2008.104331 [doi]
AB  - OBJECTIVES: To determine whether changes in levels of anti-cyclic citrullinated 
      peptide (anti-CCP) and rheumatoid factor (RF) are associated with the spontaneous 
      improvement of rheumatoid arthritis (RA) during pregnancy and with the subsequent 
      flare post partum. METHODS: Disease activity scores from the Pregnancy-induced 
      Amelioration of Rheumatoid Arthritis (PARA) study of 118 patients were available 
      for analysis. Before conception (if applicable), at each trimester and at 6, 12 
      and 26 weeks post partum, levels of the autoantibodies anti-CCP, IgM-RF, IgG-RF 
      and IgA-RF were determined. Responses in disease activity were classified 
      according to European League Against Rheumatism (EULAR) response criteria during 
      pregnancy and post partum, and associated with the presence or absence of 
      autoantibodies. RESULTS: The median levels of anti-CCP and all subclasses of RF 
      during pregnancy were stable, whereas post partum the levels of anti-CCP, IgM-RF 
      and IgA-RF declined. A significantly higher percentage of women without 
      autoantibodies (negative for anti-CCP and RF) improved compared with women 
      positive for either or both autoantibodies (75% vs 39%, p = 0.01). The occurrence 
      of a flare post partum was comparable between these groups. CONCLUSIONS: 
      Improvement of disease activity of RA during pregnancy was not associated with 
      changes in levels of autoantibodies during pregnancy, however, improvement may 
      occur more frequently in the absence of anti-CCP and RF.
FAU - de Man, Y A
AU  - de Man YA
AD  - Department of Rheumatology, Erasmus MC, University Medical Center Rotterdam, The 
      Netherlands. y.a.deman@erasmusmc.nl
FAU - Bakker-Jonges, L E
AU  - Bakker-Jonges LE
FAU - Goorbergh, C M Dufour-van den
AU  - Goorbergh CM
FAU - Tillemans, S P R
AU  - Tillemans SP
FAU - Hooijkaas, H
AU  - Hooijkaas H
FAU - Hazes, J M W
AU  - Hazes JM
FAU - Dolhain, R J E M
AU  - Dolhain RJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090311
PL  - England
TA  - Ann Rheum Dis
JT  - Annals of the rheumatic diseases
JID - 0372355
RN  - 0 (Autoantibodies)
RN  - 0 (Biomarkers)
RN  - 0 (Peptides, Cyclic)
RN  - 0 (cyclic citrullinated peptide)
RN  - 9009-79-4 (Rheumatoid Factor)
SB  - IM
MH  - Adult
MH  - Arthritis, Rheumatoid/*immunology
MH  - Autoantibodies/*blood
MH  - Biomarkers/blood
MH  - Female
MH  - Humans
MH  - Peptides, Cyclic/*immunology
MH  - Pregnancy
MH  - Pregnancy Complications/*immunology
MH  - Prognosis
MH  - Prospective Studies
MH  - Puerperal Disorders/immunology
MH  - Rheumatoid Factor/blood
MH  - Severity of Illness Index
EDAT- 2009/03/14 09:00
MHDA- 2010/02/20 06:00
CRDT- 2009/03/14 09:00
PHST- 2009/03/14 09:00 [entrez]
PHST- 2009/03/14 09:00 [pubmed]
PHST- 2010/02/20 06:00 [medline]
AID - ard.2008.104331 [pii]
AID - 10.1136/ard.2008.104331 [doi]
PST - ppublish
SO  - Ann Rheum Dis. 2010 Feb;69(2):420-3. doi: 10.1136/ard.2008.104331. Epub 2009 Mar 
      11.